Godson Oguchi

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Robert Gottlieb, Carlos Vaca, Roger Paredes et al. · New England Journal of Medicine · 2021 · 1.3K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +13

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 689 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19

Jean M. Connors, Maria M. Brooks, Frank C. Sciurba et al. · JAMA · 2021 · 263 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 180 citations

Medicine, Infectious Diseases, Pharmacology +16

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11